Compare Davita Inc (DVA) vs Corning Incorporated (GLW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Corning Incorporated — how do they compare? Davita Inc trades at $227.08 (market cap $14.92B), while Corning Incorporated trades at $174.67 (market cap $161.49B). The key difference: Corning Incorporated is far larger — about 10.8× Davita Inc's market cap, and Corning Incorporated pays a 0.6% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | GLW | |
|---|---|---|
Market Cap | $14.92B | $161.49B |
Sector | Health | Technology |
52-Week High | $235.71 | $255.79 |
52-Week Low | $103.87 | $52.52 |
Enterprise Value | $27.47B | $169.66B |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Corning (GLW) trades at $183.36, down 3.92% amid a broader AI infrastructure stock selloff. The stock shows strong fundamentals with Q1 2026 EPS beating estimates at $0.70 versus $0.692 expected, marking the fourth consecutive earnings beat. Revenue growth accelerated to $15.63 billion in 2025 with net income margin improving to 10.21%. Technical indicators show bearish momentum with the price testing support at $181, while RSI at 46.51 suggests neutral momentum conditions.
GLW presents a compelling long-term opportunity with 54% analyst buy ratings and a $210.10 consensus price target representing 15% upside. Key risks include China exposure, consumer electronics cyclicality, and competitive pressures in optical communications. The company's AI partnerships with NVIDIA and Amazon position it well for sustained growth in fiber and connectivity markets despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
